Overview

Also Known As: C57BL/6 TRAF

These TRAF1 mutant mice may be useful in studying negative regulation of tumor necrosis factor (TNF) signaling, NF-kB and AP-1 signaling, T cell receptor (TCR)-induced proliferation of T cells, Th2 responses, TRAF1/Bim function in CD8 memory T cell survival, allergic airway diseases and Rheumatoid arthritis, as well as the role of TRAF1 activation in the pathogenesis of lymphomas. Of note, TRAF1 mutant mice are available on either a BALB/c congenic (Stock No. 008074) or C57BL/6 congenic (Stock No. 008076) background.

Donating Investigator

Erdyni Tsitsikov, Immune Disease Institute (formerly CBRI)

Genetic overview

Genetic Background	Generation

Traf1^tm1Tsi

Allele Type	Gene Symbol	Gene Name
Targeted (Null/Knockout)	Traf1	TNF receptor-associated factor 1

View Genetics

Research Applications

Research Tools
Immunology, Inflammation and Autoimmunity Research
Internal/Organ Research
Cancer Research
Cell Biology Research
Apoptosis Research

View All Research Applications

Base Price

Starting at:

$2,854.50 Domestic price Cryo Recovery

View Price List

Details

Detailed Description

Mice homozygous for the TRAF1 mutant allele (TRAF1^-/-) are viable and fertile. No protein expression from the targeted gene is observed in CD40-stimulated splenocytes isolated from homozygous mice. Homozygous mice on a C57BL/6 congenic background (B6-TRAF1^-/-) have abnormal memory T cell survival and impaired influenza virus CD8 T cell responses. Activated B6-TRAF1^-/- T cells accumulate increased levels of proapoptotic BH3-only family member Bim, particularly the most toxic isoform, Bim_s. The donating investigator reports that B6-TRAF1 mutant mice may be difficult to breed and gain more weight than BALB/c-TRAF1 mutant mice.

Homozygous mice on a BALB/c congenic background (BALB/c-TRAF1^-/-) exhibit acute liver injury and elevated serum liver enzymes following intratracheal TNF-alpha treatment. Furthermore, activated TRAF1^-/- T cells have significantly increased expression of Th2 cytokines (IL-4, IL-5 and IL-13) that elicit enhanced Th2 responses in vivo. BALB/c-TRAF1^-/- T cells exhibit elevated nuclear expression of NFAT-interacting protein (NIP45) and also induce significantly more intense pulmonary inflammation and higher airway hyper-responsiveness in OVA allergic inflammation models. Pulmonary leukocyte recruitment is attenuated following inhalation of lipopolysaccharide in BALB/c-TRAF1^-/- mice. TRAF1 strains may be useful in studying negative regulation of tumor necrosis factor (TNF) signaling, NF-kB and AP-1 signaling, T cell receptor (TCR)-induced proliferation of T cells, Th2 responses, TRAF1/Bim function in CD8 memory T cell survival, allergic airway diseases and Rheumatoid arthritis, as well as the role of TRAF1 activation in the pathogenesis of lymphomas.

Of note, TRAF1 mutant mice are available on either a BALB/c (Stock No. 008074) or C57BL/6 (Stock No. 008076) congenic background.

In an attempt to offer alleles on well-characterized or multiple genetic backgrounds, alleles are frequently moved to a genetic background different from that on which an allele was first characterized. It should be noted that the phenotype could vary from that originally described. We will modify the strain description if necessary as published results become available.

Development

A targeting vector was designed to replace exons 2-5 (beginning at the first coding exon) with a neomycin resistance gene. This construct was electroporated into 129S4/SvJae-derived J1 embryonic stem (ES) cells. Correctly targeted ES cells were injected into blastocysts and the resulting chimeric males were bred with C57BL/6 females. Heterozygotes were then backcrossed to C57BL/6 inbred mice for at least 9 generations prior to arrival at The Jackson Laboratory.

A SNP (single nucleotide polymorphism) panel analysis performed by The Jackson Laboratory revealed these mice are congenic on a C57BL/6 genetic background, and that both C57BL/6N and C57BL/6J markers are present.

Control Suggestions

000664 C57BL/6J

Additional Information

Considerations for Choosing Controls

Selected References

Bryce PJ; Oyoshi MK; Kawamoto S; Oettgen HC; Tsitsikov EN. 2006. TRAF1 regulates Th2 differentiation, allergic inflammation and nuclear localization of the Th2 transcription factor, NIP45. Int Immunol 18(1):101-11PubMed: 16352630 MGI: J:104165
Sabbagh L; Srokowski CC; Pulle G; Snell LM; Sedgmen BJ; Liu Y; Tsitsikov EN; Watts TH. 2006. A critical role for TNF receptor-associated factor 1 and Bim down-regulation in CD8 memory T cell survival. Proc Natl Acad Sci U S A 103(49):18703-8PubMed: 17116875 MGI: J:118166
Oyoshi MK; Barthel R; Tsitsikov EN. 2007. TRAF1 regulates recruitment of lymphocytes and, to a lesser extent, neutrophils, myeloid dendritic cells and monocytes to the lung airways following lipopolysaccharide inhalation. Immunology 120(3):303-14PubMed: 17328785 MGI: J:122710
Zhang B; Wang Z; Li T; Tsitsikov EN; Ding HF. 2007. NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 110(2):743-51PubMed: 17405906 MGI: J:123872
Tsitsikov EN; Laouini D; Dunn IF; Sannikova TY; Davidson L; Alt FW; Geha RS. 2001. Traf1 is a negative regulator of tnf signaling. enhanced tnf signaling in traf1-deficient mice. Immunity 15(4):647-57PubMed: 11672546 MGI: J:72327
Pryhuber GS; Huyck HL; Roper JM; Cornejo J; O'reilly MA; Pierce RH; Tsitsikov EN. 2005. Acute Tumor Necrosis Factor-{alpha}-Induced Liver Injury in the Absence of Tumor Necrosis Factor Receptor-Associated Factor 1 Gene Expression. Am J Pathol 166(6):1637-45PubMed: 15920149 MGI: J:98818

View All References

Genetics

Traf1^tm1Tsi

Allele Symbol: Traf1^tm1Tsi

Allele Name	targeted mutation 1, Erdyni Y Tsitsikov
Allele Type	Targeted (Null/Knockout)
Allele Synonym(s)	Traf1^tm1Tsi; targeted mutation 1, Erdyni Y Tsitsikov
Gene Symbol and Name	Traf1, TNF receptor-associated factor 1
Gene Synonym(s)	4732496E14Rik; RIKEN cDNA 4732496E14 gene; EBI6; MGC:10353; 4732496E14Rik
Strain of Origin	129S4/SvJae
Chromosome	2
Molecular Note	The gene was disrupted by replacement of exons 2-5 with a neomycin resistance cassette. Homozygous mutant animals did not express protein product as determined by Western blot analysis of stimulated splenocytes using polyclonal antibodies directed against the C-terminus of the protein.
Mutations Made By	Erdyni Tsitsikov, Immune Disease Institute (formerly CBRI)

Disease/Phenotype

Disease Terms

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Research Tools
- Cancer Research
  - production of T cells and hybridoma
  - genes regulating lymphoma development
  - production of B and T cells, antibodies, and hybridomas
  - T cell deficiency
- Cell Biology Research
- Immunology, Inflammation and Autoimmunity Research
  - production of T cell lines and hybridomas
  - production of B cells, antibodies T cell lines, and hybridomas
  - T cell deficiency
  - T Cell Receptor Deficiency
- Genetics Research
  - Mutagenesis and Transgenesis
  - Mutagenesis and Transgenesis: transcriptional activation
- Apoptosis Research
Immunology, Inflammation and Autoimmunity Research
- Intracellular Signaling Molecules
- Lymphoid Tissue Defects
- T Cell Receptor Signaling Defects
- Immunodeficiency
  - T cell deficiency
- Autoimmunity
- Growth Factors/Receptors/Cytokines
Internal/Organ Research
- Lymphoid Tissue Defects
  - T cell deficiency
Cancer Research
- Growth Factors/Receptors/Cytokines
- Genes Regulating Growth and Proliferation
Cell Biology Research
- Genes Regulating Growth and Proliferation
- Transcriptional Regulation
- Signal Transduction
Apoptosis Research
- Endogenous Regulators

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Traf1^tm1Tsi/Traf1^tm1Tsi
involves: 129S4/SvJae * C57BL/6

cellular phenotype

increased sensitivity to induced cell death
- and hypodermis, including vacuolization and disintegration
- following subcutaneous injection of a suboptimal TNF dose (1.5 ug/day for 5 days), homozygotes display significantly more skin ulcerations and hemorrhages than wild-type controls, with complete loss of the epidermis and extensive cellular damage in dermis and hypodermis, including vacuolization and disintegration
- homozygotes display increased sensitivity to TNF-induced skin necrosis relative to wild-type controls

increased T cell proliferation
- activated mutant, but not wild-type, T cells respond to TNF by activation of the NF-kappaB and AP-1 signaling pathways
- following prestimulation with anti-CD3 mAb, activated mutant, but not wild-type, T cells, respond to TNF by proliferation, as determined by [3H]-thymidine incorporation
- Normal - however, following injection of staphylococcal enterotoxin B (SEB), homozygotes display normal superantigen-induced clonal expansion and deletion of peripheral Vbeta8-bearing T cells, as determined by changes in lymph node Vbeta8+ and Vbeta6+ subsets, BrdU incorporation of Vbeta8-bearing T cells, and apoptosis of CD4+ and CD8+ populations by annexin V-FITC staining
- in culture, mutant splenic T cells show higher proliferation to immobilized anti-CD3 mAb than wild-type T cells; however, no differences in annexin V staining, expression of CD25 (IL-2R-alpha) or intracellular IL-2 protein content are observed
- increased T cell proliferation persists following stimulation with submitogenic concentrations of anti-CD3 mAb and increasing concentrations of CD28 mAb or of recombinant IL-2
- proliferation of activated mutant T cells to TNF is abrogated by antagonistic mAb to TNF receptor superfamily, member 1b (TNFR2, p75) but not by antagonistic mAb to TNF receptor superfamily, member 1a (TNFR1, p55)
- Normal - U incorporation of Vbeta8-bearing T cells, and apoptosis of CD4+ and CD8+ populations by annexin V-FITC staining

hematopoietic system phenotype

increased lymphocyte cell number
- homozygotes show a significant increase of total lymphocyte number in inguinal lymph nodes relative to wild-type controls

increased T cell proliferation
- activated mutant, but not wild-type, T cells respond to TNF by activation of the NF-kappaB and AP-1 signaling pathways
- following prestimulation with anti-CD3 mAb, activated mutant, but not wild-type, T cells, respond to TNF by proliferation, as determined by [3H]-thymidine incorporation
- Normal - however, following injection of staphylococcal enterotoxin B (SEB), homozygotes display normal superantigen-induced clonal expansion and deletion of peripheral Vbeta8-bearing T cells, as determined by changes in lymph node Vbeta8+ and Vbeta6+ subsets, BrdU incorporation of Vbeta8-bearing T cells, and apoptosis of CD4+ and CD8+ populations by annexin V-FITC staining
- in culture, mutant splenic T cells show higher proliferation to immobilized anti-CD3 mAb than wild-type T cells; however, no differences in annexin V staining, expression of CD25 (IL-2R-alpha) or intracellular IL-2 protein content are observed
- increased T cell proliferation persists following stimulation with submitogenic concentrations of anti-CD3 mAb and increasing concentrations of CD28 mAb or of recombinant IL-2
- proliferation of activated mutant T cells to TNF is abrogated by antagonistic mAb to TNF receptor superfamily, member 1b (TNFR2, p75) but not by antagonistic mAb to TNF receptor superfamily, member 1a (TNFR1, p55)
- Normal - U incorporation of Vbeta8-bearing T cells, and apoptosis of CD4+ and CD8+ populations by annexin V-FITC staining

immune system phenotype

abnormal lymph node cell ratio
- homozygotes exhibit an increased T/B cell ratio in inguinal lymph nodes relative to wild-type controls
- Normal - however, the CD4/CD8 ratio remains normal

increased lymphocyte cell number
- homozygotes show a significant increase of total lymphocyte number in inguinal lymph nodes relative to wild-type controls

increased T cell proliferation
- activated mutant, but not wild-type, T cells respond to TNF by activation of the NF-kappaB and AP-1 signaling pathways
- following prestimulation with anti-CD3 mAb, activated mutant, but not wild-type, T cells, respond to TNF by proliferation, as determined by [3H]-thymidine incorporation
- Normal - however, following injection of staphylococcal enterotoxin B (SEB), homozygotes display normal superantigen-induced clonal expansion and deletion of peripheral Vbeta8-bearing T cells, as determined by changes in lymph node Vbeta8+ and Vbeta6+ subsets, BrdU incorporation of Vbeta8-bearing T cells, and apoptosis of CD4+ and CD8+ populations by annexin V-FITC staining
- in culture, mutant splenic T cells show higher proliferation to immobilized anti-CD3 mAb than wild-type T cells; however, no differences in annexin V staining, expression of CD25 (IL-2R-alpha) or intracellular IL-2 protein content are observed
- increased T cell proliferation persists following stimulation with submitogenic concentrations of anti-CD3 mAb and increasing concentrations of CD28 mAb or of recombinant IL-2
- proliferation of activated mutant T cells to TNF is abrogated by antagonistic mAb to TNF receptor superfamily, member 1b (TNFR2, p75) but not by antagonistic mAb to TNF receptor superfamily, member 1a (TNFR1, p55)
- Normal - U incorporation of Vbeta8-bearing T cells, and apoptosis of CD4+ and CD8+ populations by annexin V-FITC staining

mammalian phenotype

immune system phenotype
- Normal - homozygotes display normal antibody responses to T-dependent antigens (ovalbumin) and type 1 and type 2 T-independent antigens (TNP-LPS and TNP-Ficoll, respectively)
- Normal - homozygotes display normal T and B lymphocyte development, with no differences in thymus or spleen size relative to wild-type controls
- Normal - in culture, mutant splenic B cells show normal proliferation to anti-IgM and anti-CD40 stimulation as well as normal activation of NF-kappaB and AP-1 following CD40 ligation

References

Bryce PJ; Oyoshi MK; Kawamoto S; Oettgen HC; Tsitsikov EN. 2006. TRAF1 regulates Th2 differentiation, allergic inflammation and nuclear localization of the Th2 transcription factor, NIP45. Int Immunol 18(1):101-11PubMed: 16352630 MGI: J:104165
Sabbagh L; Srokowski CC; Pulle G; Snell LM; Sedgmen BJ; Liu Y; Tsitsikov EN; Watts TH. 2006. A critical role for TNF receptor-associated factor 1 and Bim down-regulation in CD8 memory T cell survival. Proc Natl Acad Sci U S A 103(49):18703-8PubMed: 17116875 MGI: J:118166
Oyoshi MK; Barthel R; Tsitsikov EN. 2007. TRAF1 regulates recruitment of lymphocytes and, to a lesser extent, neutrophils, myeloid dendritic cells and monocytes to the lung airways following lipopolysaccharide inhalation. Immunology 120(3):303-14PubMed: 17328785 MGI: J:122710
Zhang B; Wang Z; Li T; Tsitsikov EN; Ding HF. 2007. NF-kappaB2 mutation targets TRAF1 to induce lymphomagenesis. Blood 110(2):743-51PubMed: 17405906 MGI: J:123872
Tsitsikov EN; Laouini D; Dunn IF; Sannikova TY; Davidson L; Alt FW; Geha RS. 2001. Traf1 is a negative regulator of tnf signaling. enhanced tnf signaling in traf1-deficient mice. Immunity 15(4):647-57PubMed: 11672546 MGI: J:72327
Pryhuber GS; Huyck HL; Roper JM; Cornejo J; O'reilly MA; Pierce RH; Tsitsikov EN. 2005. Acute Tumor Necrosis Factor-{alpha}-Induced Liver Injury in the Absence of Tumor Necrosis Factor Receptor-Associated Factor 1 Gene Expression. Am J Pathol 166(6):1637-45PubMed: 15920149 MGI: J:98818

Additional - Traf1^tm1Tsi related

Technical Support

Contact Technical Support

Genotyping Protocols
- Standard PCR: Traf1^tm1Tsi
- Genotyping resources and troubleshooting
Breeding Considerations

When maintaining a live colony, these mice may be bred as homozygotes.
- Additional Breeding and Husbandry Support
Citation
When using the B6.129S4-Traf1^tm1Tsi/J mouse strain in a publication, please cite the originating article(s) and include JAX stock #008076 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

Pricing & Availability

Cryo Recovery

Domestic
International

Live Mouse

Age

Genotype

Price

weeks

Cryorecovery - Pricing

Service	Genotype	Price
	Heterozygous for Traf1<tm1Tsi>

We will fulfill your order by providing at least two carriers for each strain ordered. The total number, sex, and genotypes provided will vary, although typically 8 or more animals are provided. Please check genotypes which will be recovered. While the genotypes of all animals produced will be communicated to you prior to scheduling shipment, the genotypes of animals provided may not reflect the mating scheme and genotypes described in the strain description. Animals are typically ready to ship in 11-14 weeks. If a second recovery is required to produce the minimum number of animals, then delivery time would increase to approximately 25 weeks. If we fail to produce animals of the correct genotype, you will not be charged. We cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.

Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation.

Related Products and Services

Frozen Mouse Embryo

$2,595.00 per straw or vial

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

Terms Of Use

Terms of Use

General Terms and Conditions

Questions about Terms of Use

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Also Known As: C57BL/6 TRAF

Donating Investigator

Genetic overview

Research Applications

Base Price

Detailed Description

Development

Control Suggestions

Additional Information

Selected References

Traf1tm1Tsi

Allele Symbol: Traf1tm1Tsi

Disease Terms

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Mammalian Phenotype Terms by Genotype

Genotype: Traf1tm1Tsi/Traf1tm1Tsiinvolves: 129S4/SvJae * C57BL/6

cellular phenotype

hematopoietic system phenotype

immune system phenotype

mammalian phenotype

References

Additional - Traf1tm1Tsi related

Genotyping Protocols

Breeding Considerations

Citation

Animal Health Reports

Production of mice from cryopreserved embryos or sperm occurs in a maximum barrier room, G200

Live Mouse

Cryorecovery - Pricing

Related Products and Services

Payment Terms and Conditions

The Jackson Laboratory's Genotype Promise

Terms of Use

Licensing Information

JAX® Mice, Products & Services Conditions of Use

No Warranty

Credit for PRODUCTS or SERVICES

Animal Care and Use for SERVICES

No Liability

Traf1^tm1Tsi

Allele Symbol: Traf1^tm1Tsi

Genotype: Traf1^tm1Tsi/Traf1^tm1Tsi
involves: 129S4/SvJae * C57BL/6

Additional - Traf1^tm1Tsi related